Sagimet Biosciences (SGMT) Total Current Liabilities (2022 - 2026)

Sagimet Biosciences' Total Current Liabilities history runs 5 years deep, the most recent figure standing at $5.3 million for Q1 2026.

• In Q1 2026, Total Current Liabilities changed N/A year-over-year to $5.3 million; the TTM figure through Mar 2026 stood at $5.3 million (changed N/A YoY), while the FY2025 annual figure was $5.1 million, up 14.53% from the prior year.
• Total Current Liabilities was $5.3 million for Q1 2026 at Sagimet Biosciences, up from $5.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $9.1 million in Q3 2025 to a low of $4.5 million in Q4 2024.
• Historically, Total Current Liabilities has averaged $5.8 million across 5 years, with a median of $5.3 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Total Current Liabilities fell 21.22% in 2024, then rose 14.53% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $5.3 million in 2022, then grew by 7.1% to $5.7 million in 2023, then dropped by 21.22% to $4.5 million in 2024, then advanced by 14.53% to $5.1 million in 2025, then gained by 3.84% to $5.3 million in 2026.
• The last three Total Current Liabilities figures came in at $5.3 million (Q1 2026), $5.1 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.